Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER
Commercial Sponsor
Pfizer
Summary
This is a randomised, open-label study with an Experimental arm and an Active comparator arm. In the Experimental Arm, participants will receive Lorlatinib, administered orally once daily, at a dose of 100mg. In the Active Comparator Arm, participants will receive Crizotinib, administered orally twice daily, at a dose of 250mg.